ESMO Asia 2016 Congress

Oncology Meeting Resources

16 Dec - 19 Dec 2016, Singapore

ESMO Asia 2016 Square

The ESMO Asia Congress comprised both scientific and educational tracks prepared by an international scientific committee. There was a strong emphasis on state of the art science, including a call for abstracts, and the current standard of care across all major tumour types.

Abstracts, presentations and webcasts from the ESMO Asia 2016 Congress are now available here to ESMO members. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Useful Links





Format available

http://oncologypro.esmo.org/Meeting-Resourc...ediates-immune-escape-in-lung-adenocarcinoma

BackgroundProgrammed death-ligand 1 (PD-L1) expression is associated with EGFR mutation and EML4-ALK rearrangement. Whether PD-L1 is regulated by other driver mutations like KRAS in lung adenocarcinoma...

Date: 19 Dec 2016
Presenter: Shaodong Hong
Resources: Abstract
Topics: Cancer Immunology and Immunotherapy, Lung and other Thoracic Tumours, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...ogic-subtype-in-resected-lung-adenocarcinoma

BackgroundOnly a minority of patients benefit from adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC) and merely with an increase of 4% at five years overall survival.

Date: 19 Dec 2016
Presenter: Zhong-Yi Dong
Resources: Abstract
Topics: Non-Small-Cell Lung Cancer, Early Stage, Cancer Immunology and Immunotherapy

http://oncologypro.esmo.org/Meeting-Resourc...ll-responses-in-lung-squamous-cell-carcinoma

BackgroundImmune checkpoint inhibitors targeting PD-1/PD-L1 have shown striking response in lung squamous cell carcinoma (SQCLC). However, the response rate was only about 20%.

Date: 19 Dec 2016
Presenter: Shu-Mei Huang
Resources: Abstract
Topics: Cancer Immunology and Immunotherapy, Lung and other Thoracic Tumours

http://oncologypro.esmo.org/Meeting-Resourc...e-metastases-in-submucosal-colorectal-cancer

BackgroundIn colorectal cancer (CRC), the possibility of lymph node (LN) metastases is important to select the treatment. According to the Japanese Society for Cancer of the Colon and Rectum guidelines...

Date: 19 Dec 2016
Presenter: Shiki Fujino
Resources: Abstract
Topics: Colon Cancer, Rectal Cancer, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...nalysis-of-the-phase-1-2-CheckMate-040-study

BackgroundMedian overall survival (OS) for first-line (1L) treatment of advanced hepatocellular carcinoma (aHCC) with sorafenib (sor) is up to 11 mo and 7–8 mo with best supportive care (BSC) post-sor failure.

Date: 19 Dec 2016
Presenter: Ignacio Melero
Resources: Abstract
Topics: Hepatobiliary Cancers, Cancer Immunology and Immunotherapy

http://oncologypro.esmo.org/Meeting-Resourc...ve-resection-of-metastatic-colorectal-cancer

BackgroundLymph node (LN) status is one of the most important predictors for M0 colorectal cancer patients. However, its clinical impact on stage IV colorectal cancer remains unclear.

Date: 19 Dec 2016
Presenter: Qingguo Li
Resources: Abstract
Topics: Colon Cancer, Rectal Cancer, Pathology/Molecular Biology, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ine-therapy-in-advanced-gastric-and-gastroes

BackgroundClaudin(CLDN)18.2 is a stomach specific tight junction protein. The chimeric monoclonal anti-CLDN18.2 antibody IMAB362 potently activates complement and antibody dependent cellular cytotoxicity.

Date: 19 Dec 2016
Presenter: Florian Lordick
Resources: Abstract
Topics: Drug Development, Gastric Cancer